What is the consensus rating for MLNT stock?
The consensus rating for MELINTA THERAPEUTICS INC (MLNT) is 60 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
MELINTA THERAPEUTICS INC (MLNT) Forecast, Price Target & Analyst Ratings
NASDAQ:MLNT
Current stock price
0.5
-0.03 (-5.7%)
At close:
0.51
+0.01 (+2%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for MELINTA THERAPEUTICS INC (MLNT).
Forecast Snapshot
Price Target Details & History
Consensus Price Target and Range
Mean target
N/A
Upside
N/A
From current price of $0.50 to mean target of N/A, Based on 3 analyst forecasts
Low
N/A
Median
N/A
High
N/A
Price Target Revisions
1 Month
N/A
3 Months
N/A
Price Target Summary
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
60.00%
MLNT was analyzed by 3 analysts. The buy percentage consensus is at 60. So analysts seem to be rather neutral about MLNT.
In the previous month the buy percentage consensus was at a similar level.
Only 3 analysts analyzed MLNT. So this is just the average opinion of a couple of analysts.
Recent Upgrades & Downgrades
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
N/A
EPS (3 Months)
N/A
Next Earnings Summary
Full Analyst Estimates
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
N/A
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
N/A
Revenue Next 5 Year
N/A
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A